Search hospitals > Massachusetts > Lowell

Lowell General Hospital

Claim this profile
Lowell, Massachusetts 01854
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Non-Small Cell Lung Cancer
110 reported clinical trials
5 medical researchers
Photo of Lowell General Hospital in LowellPhoto of Lowell General Hospital in Lowell

Summary

Lowell General Hospital is a medical facility located in Lowell, Massachusetts. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer and other specialties. Lowell General Hospital is involved with conducting 110 clinical trials across 166 conditions. There are 5 research doctors associated with this hospital, such as Murat A. Anamur, Anasuya Gunturi, Sarah Paraghamian, and Matthew S. Katz.

Area of expertise

1Breast Cancer
Global Leader
Lowell General Hospital has run 44 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 positive
PR positive
2Cancer
Global Leader
Lowell General Hospital has run 38 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive

Top PIs

Clinical Trials running at Lowell General Hospital

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Gallbladder Cancer
Bladder Cancer
Colorectal Cancer
Cancer
ALK Gene Rearrangement
Thyroid Cancer
Recurrence
Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Lowell General Hospital?
Lowell General Hospital is a medical facility located in Lowell, Massachusetts. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer and other specialties. Lowell General Hospital is involved with conducting 110 clinical trials across 166 conditions. There are 5 research doctors associated with this hospital, such as Murat A. Anamur, Anasuya Gunturi, Sarah Paraghamian, and Matthew S. Katz.